GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Valneva SE
Valneva is a European biotechnology company specializing in vaccine development. Its stock price is highly volatile, driven by news of its clinical trials of vaccines against diseases such as Lyme disease and chikungunya, as well as its experience developing a COVID-19 vaccine.
Share prices of companies in the market segment - Pharma virus
Valneva (VALN) is a specialized vaccine company focused on the development and commercialization of prophylactic vaccines against infectious diseases. We classify it in the Pharmaceuticals/Virology segment. The chart below reflects the dynamics of this sector, which is important for global health.
Broad Market Index - GURU.Markets
Valneva is a French biotechnology company specializing in the development and production of vaccines against infectious diseases. It is a component of the GURU.Markets index, representing the vaccine sector. The chart below shows the US market. See how Valneva shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
VALN - Daily change in the company's share price Valneva SE
For Valneva, a biopharmaceutical company specializing in vaccines, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials and disease outbreaks. This metric isn't just noise, but a critical component of the models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
Valneva SE is a biotech company specializing in vaccines. This chart highlights the sector's extreme volatility. Comparing it to VALN, whose success depends on vaccine approval and sales, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Valneva is a biopharmaceutical company specializing in vaccine development. The vaccine sector is highly volatile and driven by news about clinical trials. The chart below reflects average fluctuations in this industry, providing context for Valneva's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Valneva SE
Valneva is a European biotech company specializing in vaccine development. Its shares are extremely sensitive to news about clinical trials and disease outbreaks. This event-driven volatility is a clear example of how biotech influences the entire market.
Annual dynamics of market capitalization of the market segment - Pharma virus
Valneva SE is a specialized vaccine company. Its portfolio includes travel vaccines and candidates for emerging threats. The chart shows how its unique niche, clinical trial results, and competition in the vaccine industry influence its volatility.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Valneva, a European vaccine manufacturer, lives in a world of science and epidemics. Its share price (ADR) is not driven by the economy, but by the success of its clinical trials and demand for travel vaccines. The chart tells the story of how the biotech company is trying to find its next big hit.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Valneva SE
Valneva, a biotech company, is valued based on its product cycle. Monthly fluctuations on the chart reflect sales of its travel vaccines, as well as news about clinical trials of new vaccines, such as the Lyme disease vaccine, the success of which is crucial to its growth.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Its success depends on the results of clinical trials and government contracts. The chart below reflects investor sentiment across the vaccine sector, which provides important context for Valneva.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Valneva SE is a European biotech company specializing in vaccines. Its shares are highly sensitive to news about the development and approval of vaccines (for example, for COVID-19 or Lyme disease). The company's performance is event-driven and largely independent of overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Valneva SE
For Valneva, a European biotech company specializing in vaccines, weekly performance is extremely volatile. News about the progress of clinical trials of new vaccines (for example, for Lyme disease), government contracts, or disease outbreaks trigger sharp price movements.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Valneva shares, like those of the entire vaccine sector, are moving against a backdrop of news about disease outbreaks and regulatory decisions. Investor sentiment toward the entire industry is creating high volatility. The chart will show how the company stacks up against this backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Valneva, like many biotech companies, can exhibit dynamics completely unrelated to the market. News about disease outbreaks or vaccine approvals can cause its shares to surge even on the day the S&P 500 is plunging. The chart will reveal these moments.
Market capitalization of the company, segment and market as a whole
VALN - Market capitalization of the company Valneva SE
Valneva's market capitalization chart is a financial valuation of the European biotech company specializing in vaccines. It reflects both its commercial products (vaccines for travelers) and its development pipeline, including vaccines for Lyme disease and chikungunya. Its volatile dynamics are a story of ups and downs during the COVID-19 pandemic and a return to its core strategy.
VALN - Share of the company's market capitalization Valneva SE within the market segment - Pharma virus
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Its share of the pharmaceutical sector reflects its unique portfolio of vaccines, including those against Lyme disease and chikungunya. The chart shows the company's position in preventive medicine.
Market capitalization of the market segment - Pharma virus
Valneva is a specialized vaccine company. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect both successes in the fight against diseases and the high risks of development. Valneva occupies a unique niche, focusing on vaccines for travelers and against endemic diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vaccine development, as shown in the chart, is critical to public health. Valneva SE is a European biotechnology company specializing in vaccines against infectious diseases. Its market capitalization is a valuation of its vaccine portfolio and its scientific platform.
Book value capitalization of the company, segment and market as a whole
VALN - Book value capitalization of the company Valneva SE
Valneva's chart represents the material basis for vaccine development. The growth in its book value reflects the value of its European production facilities and R&D centers. These are the physical assets that enable the company to develop and produce vaccines against diseases such as Lyme disease and chikungunya.
VALN - Share of the company's book capitalization Valneva SE within the market segment - Pharma virus
Valneva, a specialized vaccine company, controls important production assets. Its stake in the sector includes factories in Europe for the production of vaccines against encephalitis, cholera, and COVID-19. This physical base is key to its ability to respond to global health threats.
Market segment balance sheet capitalization - Pharma virus
Valneva is a vaccine company. The pharmaceutical industry, as the chart shows, is capital-intensive. Valneva is a vertically integrated player. It owns factories that produce vaccines against Japanese encephalitis and cholera, which is its unique asset.
Book value of all companies included in the broad market index - GURU.Markets
Valneva SE is a European biotechnology company specializing in vaccines. Its book value comes from its European production facilities and the capital it invests in the development and commercialization of vaccines against diseases such as chikungunya and Lyme disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Valneva SE
Valneva is a biotechnology company. Its valuation reflects its portfolio of commercial vaccines and its developments, including a unique Lyme disease vaccine with significant market potential.
Market to book capitalization ratio in a market segment - Pharma virus
Valneva is a biotechnology company specializing in the development and production of vaccines against infectious diseases. Its value is determined by both current sales and the potential for new vaccines in development. The chart shows how the market values this balance relative to its manufacturing and research assets.
Market to book capitalization ratio for the market as a whole
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Compared to average market valuations, as shown in this chart, its valuation is highly volatile and depends on the success of its vaccine candidates in clinical trials and their commercial potential.
Debts of the company, segment and market as a whole
VALN - Company debts Valneva SE
Valneva is a specialized vaccine company. Vaccine development and production is a long, risky, and extremely capital-intensive process, requiring investment in research, clinical trials, and the construction of production facilities. This chart shows how the company funds its complex and vital business pipeline.
Market segment debts - Pharma virus
Valneva is a European biotechnology company specializing in vaccine development. Vaccine development and production are capital-intensive processes. The company's financial performance reflects its successes and failures in clinical trials and product commercialization. This chart shows how the company finances its operations.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Valneva SE
Valneva SE is a European biotech company specializing in vaccines. This chart shows its financial structure. For a company whose revenue depends on the successful development and commercialization of vaccines, debt management is critical. High debt can create pressure on the company during periods between successful product launches.
Market segment debt to market segment book capitalization - Pharma virus
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Vaccine development is a lengthy and capital-intensive process. This chart shows the overall debt burden in the pharmaceutical industry, allowing us to assess how Valneva finances its expensive clinical programs and manufacturing facilities.
Debt to book value of all companies in the market
Valneva SE is a European biotechnology company specializing in vaccines. Vaccine development and production is a capital-intensive and risky process, requiring significant investment. This chart helps explain how Valneva finances its expensive programs, balancing government contracts, equity, and debt.
P/E of the company, segment and market as a whole
P/E - Valneva SE
This chart shows the valuation of Valneva, a biotech company specializing in vaccines. Its price-to-earnings ratio (if it has one) is highly dependent on the success of its developments. It's a binary bet: the success of a new vaccine (for example, for Lyme disease) could lead to explosive growth, while failure could lead to a sharp decline in valuation.
P/E of the market segment - Pharma virus
Valneva is a European biotechnology company focused on developing and commercializing vaccines to prevent infectious diseases with unmet medical needs. This chart shows the average valuation for the sector, providing investors with context for evaluating Valneva's research pipeline and commercial products.
P/E of the market as a whole
Valneva is a European biotech company specializing in vaccine development. Its valuation depends on the success of its vaccine candidates (for example, for Lyme disease) and the commercial performance of its already approved vaccines. Overall market sentiment, reflected in this chart, has little impact on its valuation, which is driven by news from the medical and epidemiological worlds.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Valneva SE
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Its future depends on the success of clinical trials and the commercialization of new vaccines. This chart shows how investors assess the company's scientific potential and future revenue from its vaccine portfolio.
%20P%2FE%20Valneva%20SE&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Valneva-SE&v=1772513540528 "Chart of the company's future (projected) P/E Valneva SE")
Future (projected) P/E of the market segment - Pharma virus
Valneva is a European biotechnology company specializing in the development and commercialization of vaccines against infectious diseases. This chart shows general expectations for the pharmaceutical sector. VALNEVA's position relative to the average reflects market opinion on its vaccine portfolio, including vaccines for Lyme disease and chikungunya, and its manufacturing capabilities.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772513540548 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Valneva SE is a European biotech company specializing in vaccines. Its valuation depends on the success of developments, government contracts, and the infectious disease situation. This overall market sentiment curve influences investor willingness to finance capital-intensive vaccine development with an uncertain commercial future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513540556 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Valneva SE
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases, such as Lyme disease and chikungunya. Its financial performance, shown in the graph, depends on sales of existing vaccines and the success of developing and commercializing new ones.
Profit of companies in the market segment - Pharma virus
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases, including Lyme disease and chikungunya. This chart shows the overall profitability of the viral pharmaceuticals sector. It reflects global investment in infectious disease prevention and the commercial potential of new vaccines.
Overall market profit
Valneva, a European biotechnology company, specializes in the development and production of vaccines against infectious diseases. Its success depends on the results of clinical trials and government vaccine procurement. General economic cycles, reflected in this chart, have less of an impact on its business than the epidemiological situation and the needs of healthcare systems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Valneva SE
Valneva SE is a biotechnology company specializing in the development and production of vaccines against infectious diseases. Its financial success depends on the commercialization of existing vaccines and the development of new ones. This chart reflects analyst expectations for sales of its Japanese encephalitis and cholera vaccines, as well as progress in developing other candidates.
%20profit%20of%20the%20company%20Valneva%20SE&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Valneva-SE&v=1772513540717 "Graph of future (projected) profit of the company Valneva SE")
Future (predicted) profit of companies in the market segment - Pharma virus
Valneva is a biotech company specializing in the development and production of vaccines against infectious diseases, including Lyme disease and chikungunya. Its success depends on the results of clinical trials and government contracts. This chart shows profitability forecasts for the entire pharmaceutical sector, helping to assess Valneva's potential in the important niche of preventive medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772513540750 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Valneva SE is a European biotechnology company specializing in vaccines. Its revenue depends on the successful development, production, and sale of vaccines (for example, against Lyme disease or COVID-19). General economic cycles, reflected in this chart, have only an indirect impact on its core business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513540756 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Valneva SE
Valneva is a biotech company specializing in the development and production of vaccines, including those for Lyme disease and chikungunya. This chart shows how the market values its vaccine portfolio. Sharp fluctuations in this indicator are often associated with news about clinical trials, regulatory approvals, or government contracts for its products.
P/S market segment - Pharma virus
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Revenue is generated through sales of existing vaccines and partnerships. This pharmaceutical sector chart helps assess the market's perception of Valneva's vaccine portfolio and research platform.
P/S of the market as a whole
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. The company's portfolio includes both commercial vaccines and promising developments. This market valuation chart provides context for understanding how investors assess the risks and potential of the vaccine business.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Valneva SE
Valneva is a specialty vaccine company focused on developing and commercializing prophylactic vaccines against infectious diseases with unmet medical needs. This chart shows how investors estimate the future sales of its vaccines, including those for Lyme disease and chikungunya, as well as revenue from existing products.
%20P%2FS%20Valneva%20SE&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Valneva-SE&v=1772513540836 "The graph of the company's future (projected) P/S Valneva SE")
Future (projected) P/S of the market segment - Pharma virus
Valneva SE is a European biotechnology company specializing in the development and commercialization of vaccines against infectious diseases. Its portfolio includes vaccines against Japanese encephalitis, cholera, and chikungunya. The company's valuation reflects sales expectations for these vaccines and the potential of its technology platforms.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772513540861 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Valneva SE is a European biotechnology company specializing in vaccine development and production. Its success depends on clinical results and the epidemiological situation. In the overall revenue growth picture illustrated by the chart, Valneva represents an important public health sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513540899 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Valneva SE
Valneva is a company specializing in the development and commercialization of vaccines. This chart shows revenue generated from sales of its commercial travel vaccines (against Japanese encephalitis and cholera), as well as from payments under partnership agreements for the development of new vaccines.
Sales of companies in the market segment - Pharma virus
Valneva (VALN) is a specialized vaccine company. It develops and commercializes prophylactic vaccines against infectious diseases with unmet medical needs, such as Lyme disease and chikungunya. This chart shows revenue in the viral pharmaceuticals sector, where Valneva is one of the few independent players in this market.
Overall market sales
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Demand for its products (such as travel vaccines) depends on global mobility. This graph, reflecting economic activity, correlates with the growth of business and leisure travel, which directly impacts Valneva's sales.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Valneva SE
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. Its revenue depends on sales of existing vaccines (such as those for Japanese encephalitis) and the success of new developments. This chart reflects analyst revenue forecasts, which are an assessment of its product portfolio and commercial potential.
%20sales%20of%20the%20company%20Valneva%20SE&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Valneva-SE&v=1772513541045 "Schedule of future (projected) sales of the company Valneva SE")
Future (projected) sales of companies in the market segment - Pharma virus
Valneva is a specialized vaccine company focused on preventative vaccines against infectious diseases. This forecast chart details the expected sales of their commercial vaccines (for example, for Japanese encephalitis) and the potential for development. This shows which products the company is focusing on for growth.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772513541092 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Valneva is a specialized vaccine company developing and commercializing prophylactic vaccines against infectious diseases. Its success depends on the results of clinical trials and government contracts. This schedule, reflecting the overall state of the economy, influences healthcare system budgets and their willingness to enter into contracts for new vaccines.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513541194 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Valneva SE
Valneva SE is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. The company's profitability depends on the successful commercialization of its vaccines, such as those for Japanese encephalitis and, potentially, Lyme disease. The chart shows how the company converts its scientific research into financial returns.
Market segment marginality - Pharma virus
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. This graph shows its path to profitability. Success depends on the commercialization of approved vaccines (such as the one for Japanese encephalitis) and the successful completion of trials of new vaccines, such as the Lyme disease vaccine.
Market marginality as a whole
Valneva SE is a European biotech company specializing in vaccine development. Its success depends on clinical trial results and its ability to compete with pharmaceutical giants. This total return chart reflects the global investment climate, demonstrating investors' willingness to fund new vaccines in a post-pandemic world.
Employees in the company, segment and market as a whole
Number of employees in the company Valneva SE
Valneva is a biotechnology company specializing in vaccine development and production. Its staff includes scientists, manufacturing specialists, and clinical trial specialists. The increase in this graph may be due to the advancement of new vaccines (for example, for Lyme disease) or the expansion of production capacity.
Share of the company's employees Valneva SE within the market segment - Pharma virus
Valneva is a specialized vaccine company developing, manufacturing, and commercializing vaccines against infectious diseases. It is a fully integrated business. This chart shows the number of scientists, production personnel, and commercial specialists required to complete the entire vaccine cycle from the laboratory to the market.
Number of employees in the market segment - Pharma virus
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines. This chart, reflecting employment in the viral pharmacology sector, demonstrates the global importance and scientific complexity of this field. For Valneva, which has unique vaccines (for example, for Lyme disease and chikungunya), growth in the sector represents both opportunities and competition.
Number of employees in the market as a whole
Valneva is a specialized vaccine company. Its staff of scientists and production specialists is growing in response to the development and commercialization of vaccines for diseases such as chikungunya and Lyme disease. The company's growth is driven by public health needs, which are a constant factor, regardless of economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Valneva SE (VALN)
Valneva is a European biotechnology company specializing in the development and production of vaccines against infectious diseases. The company's business combines scientific research and capital-intensive manufacturing. This metric reflects how the market values its vaccine portfolio and value-creating manufacturing capabilities.
%20of%20the%20company%20Valneva%20SE%20(VALN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Valneva-SE-VALN&v=1772513541465 "Chart of market capitalization per employee (in thousands of dollars) of the company Valneva SE (VALN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Valneva is a company specializing in vaccine development and production. In this field, value is created through scientific research and manufacturing capacity. This chart shows how the market values the company's vaccine portfolio (both existing and in development) relative to its workforce.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772513541503 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Valneva is a European biotechnology company specializing in vaccine development and production. The chart shows how the market values a company with its own production facilities and vaccine portfolio. It reflects the value of both current sales and the research potential of its team of scientists working on new drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513541535 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Valneva SE (VALN)
Valneva is a European biotech company specializing in vaccines (for example, against Lyme disease and chikungunya). Vaccine development and production is a complex and expensive process. This chart shows how effectively the company commercializes its approved vaccines and invests in R&D to develop new ones.
%20Chart%20Valneva%20SE%20(VALN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Valneva-SE-VALN&v=1772513541565 "Company Profit Per Employee (in thousands of dollars) Chart Valneva SE (VALN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Valneva is a European biotech company specializing in vaccines. They have developed vaccines against Japanese encephalitis, cholera, and, most recently, chikungunya. This figure reflects the transition from the R&D phase to commercialization, where revenue from vaccine sales should cover production and R&D costs.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772513541645 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Valneva SE is a European biotech company specializing in vaccines. They have developed vaccines against Japanese encephalitis (Ixiaro) and cholera (Dukoral), as well as a COVID-19 vaccine. Vaccine production is a complex and capital-intensive process. This chart shows how a biotech with commercial products (not just R&D) generates revenue from its research and production staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513541659 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Valneva SE (VALN)
Valneva is a specialized vaccine company developing and commercializing prophylactic vaccines against infectious diseases. Revenue per employee reflects the success of its commercial products and R&D programs. The chart shows how travel vaccine sales and partnership revenue drive the company's financial results.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Valneva-SE-VALN&v=1772513541765 "Sales chart per company employee Valneva SE (VALN)")
Sales per employee in the market segment - Pharma virus
Valneva (VALN) is a European biotech company specializing in the development and production of vaccines, including those for chikungunya and Lyme disease. This chart shows the average revenue per employee in the segment. It helps assess how effectively Valneva generates vaccine sales through its team.
Sales per employee for the market as a whole
Valneva (VALN) is a European biotechnology company specializing in the development and production of vaccines, including travel vaccines (for Japanese encephalitis) and a COVID-19 vaccine. This metric reflects how efficiently the company produces and markets its vaccines. It can be volatile, particularly due to large government vaccine orders.
Short shares by company, segment and market as a whole
Shares shorted by company Valneva SE (VALN)
Valneva (VALN) is a European biotech company specializing in vaccines, particularly against Lyme disease and chikungunya. The company has also been trying to develop a COVID vaccine. This chart shows a bearish sentiment. The rise in short positions may be related to disappointment following the COVID vaccine failure and doubts about the commercial potential of its current developments in niche markets. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Valneva-SE-VALN&v=1772513541847 "Short Shares Chart for the Company Valneva SE (VALN)")
Shares shorted by market segment - Pharma virus
Valneva is a European biotech company specializing in vaccines, including the Chikungunya vaccine and the (failed) COVID vaccine. This chart shows the overall sentiment in the sector. It reflects investor skepticism toward vaccine companies following the pandemic, with expectations of a decline in demand.
Shares shorted by the overall market
Valneva (VALN) is a European biotech company specializing in vaccines, including those for Lyme disease and Chikungunya. Vaccine development is a long and expensive process. This chart shows the level of uncertainty surrounding the success of these vaccines. Bears are betting that vaccine trials will not show sufficient efficacy or that competitors (such as Pfizer in the Lyme vaccine race) will be the first to deliver.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Valneva SE (VALN)
Valneva is a European biotech company specializing in vaccines. They successfully launched a Chikungunya vaccine and are working on Lyme disease. This chart measures how investors value their niche portfolio. It shows when the stock is overbought on approval news or oversold amid commercial setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Valneva-SE-VALN&v=1772513541974 "RSI 14 indicator chart for the company's stock Valneva SE (VALN)")
RSI 14 Market Segment - Pharma virus
Valneva is a European biotech company specializing in vaccine development and production. They have developed vaccines against Japanese encephalitis, cholera, and the recently approved Chikungunya vaccine (IXCHIQ). This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Valneva compares to that.
RSI 14 for the overall market
Valneva (VALN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VALN (Valneva SE)
Valneva (VALN) is a European biotechnology company specializing in the development and commercialization of vaccines, including those for Lyme disease and Chikungunya. This chart summarizes analyst opinions, reflecting their expectations for sales of existing vaccines and the success of new developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VALN-Valneva-SE&v=1772513542053 "A chart showing analyst consensus forecasts for the expected stock price. VALN (Valneva SE)")
The difference between the consensus estimate and the actual stock price VALN (Valneva SE)
Valneva is a European biotech company specializing in the development and production of vaccines, including those for Lyme disease and Chikungunya. This chart shows the gap between the current market valuation and analysts' target price. It highlights the potential experts see in their portfolio of vaccines for niche but dangerous diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VALN-Valneva-SE&v=1772513542059 "A chart showing the difference between the consensus forecast and the actual stock price. VALN (Valneva SE)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Valneva is a European biotech company specializing in the development and production of vaccines, including those for "forgotten" diseases (Chikungunya) and travel-related diseases (Japanese encephalitis). This chart shows analysts' overall expectations for the entire vaccine sector. It reflects whether experts believe this niche market will grow.
Analysts' consensus forecast for the overall market share price
Valneva SE is a European biotech company specializing in vaccines. They produce vaccines against exotic diseases (Japanese encephalitis) and are developing new ones (Lyme disease). This chart shows overall market sentiment. For Valneva, which operates at the intersection of biotech and the vaccine industry, it's important to understand how these expectations (risk appetite) influence R&D. (347)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Valneva SE
Valneva (VALN) is a European biotech company specializing in vaccines. They have commercial vaccines (for Japanese encephalitis) and an R&D pipeline (for Lyme disease and chikungunya). This chart is an indicator of their R&D platform. It weighs their current revenue from niche vaccines against the market's belief that their new developments (especially for Lyme disease) will be blockbusters.
AKIMA Market Segment Index - Pharma virus
Valneva (VALN) is a European biotech focused on vaccines; the company develops and markets vaccines for travelers (Japanese encephalitis, cholera) and (recently) for Lyme disease and Chikungunya. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche (vaccine) R&D model (VALN) differentiate it from the average pharma company?
The AKIM Index for the overall market
Valneva is a French company specializing in vaccines for travelers and against endemic diseases (Chikungunya, Lyme). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this commercial biotech story, dependent on tourism and regulations, compares to overall economic trends.
